← Back to Search

Procedure

Deep Brain Stimulation for Parkinson's Disease (MOPSO PIGD Trial)

Q: Who is eligible to enroll in this research project?

In order to be considered for acceptance, potential participants of this trial must have a diagnosis of <a href="https://www.withpower.com/clinical-trials/parkinson&#x27;s-disease">Parkinson's disease</a> and fall between 18-90 years old. Currently, the clinical trial is attempting to recruit 60 individuals in total.

Q: Does this research trial include participants of advanced age?

To be eligible for this clinical trial, potential participants must have an age that falls between 18 and 90 years old. Additionally, there are 24 trials designed specifically for young patients aged below 18 and 506 study sites targeting the elderly population over 65.

Q: Does this research project still have openings for volunteers?

The information hosted on clinicaltrials.gov displays that this trial is presently recruiting patients. It was initially posted on May 25th 2021 and the latest update occurred in May 30th 2023.

Q: How many participants are being admitted to this clinical research?

Affirmative, clinicaltrials.gov's records demonstrate that this medical experiment is actively enrolling patients since its initial posting date of May 25th 2021 and most recent update on May 30th 2023. To reach completion, 60 individuals must be recruited from 1 location.

Phase < 1

Recruiting

Led By Scott Cooper, MD, PhD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 45 seconds

Awards & highlights

MOPSO PIGD Trial Summary

This trial tests how best to adjust electrical stimulation for Parkinson's disease to maximize benefit and minimize side effects.

Who is the study for?

This trial is for Parkinson's Disease patients with bilateral deep brain stimulation (DBS) who've had a specific type of MRI and CT scan, and have been using their neurostimulators for at least 3 months. It excludes those with dementia, pregnancy, or other conditions affecting movement beyond PD.Check my eligibility

What is being tested?

The study tests personalized stimulator settings in DBS patients to improve gait and balance issues. Using advanced imaging techniques, the trial aims to optimize electrical current delivery to targeted brain areas within approved safety limits.See study design

What are the potential side effects?

While not explicitly listed here, common side effects of DBS can include headache, confusion, difficulty concentrating, stroke-like symptoms, temporary pain and swelling at implantation site.

MOPSO PIGD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 45 seconds

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~45 seconds

This trial's timeline: 3 weeks for screening, Varies for treatment, and 45 seconds for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Gait test

Secondary outcome measures

Balance Test

Bradykinesia test

Rigidity Test

MOPSO PIGD Trial Design

2Treatment groups

Experimental Treatment

Group I: STN DBSExperimental Treatment1 Intervention

Patients with implanted STN DBS leads will be allocated to this group for DBS stimulation of the STN, within FDA-approved limits and labeling, for symptoms of PD.

Group II: GP DBSExperimental Treatment1 Intervention

Patients with implanted GP DBS leads will be allocated to this group for DBS stimulation of the GP, within FDA-approved limits and labeling, for symptoms of PD.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor

1,381 Previous Clinical Trials

1,588,915 Total Patients Enrolled

Scott Cooper, MD, PhDPrincipal InvestigatorUniversity of Minnesota

Media Library

GP DBS (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05893186 — Phase < 1

Parkinson's Disease Research Study Groups: STN DBS, GP DBS

Parkinson's Disease Clinical Trial 2023: GP DBS Highlights & Side Effects. Trial Name: NCT05893186 — Phase < 1

GP DBS (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05893186 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is eligible to enroll in this research project?

"In order to be considered for acceptance, potential participants of this trial must have a diagnosis of Parkinson's disease and fall between 18-90 years old. Currently, the clinical trial is attempting to recruit 60 individuals in total."

Answered by AI

Does this research trial include participants of advanced age?

"To be eligible for this clinical trial, potential participants must have an age that falls between 18 and 90 years old. Additionally, there are 24 trials designed specifically for young patients aged below 18 and 506 study sites targeting the elderly population over 65."

Answered by AI

Does this research project still have openings for volunteers?

"The information hosted on clinicaltrials.gov displays that this trial is presently recruiting patients. It was initially posted on May 25th 2021 and the latest update occurred in May 30th 2023."

Answered by AI

How many participants are being admitted to this clinical research?

"Affirmative, clinicaltrials.gov's records demonstrate that this medical experiment is actively enrolling patients since its initial posting date of May 25th 2021 and most recent update on May 30th 2023. To reach completion, 60 individuals must be recruited from 1 location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder

2021. "Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05893186.